This study investigates the interaction between the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and alpha-synuclein, a key protein in Parkinson's disease, to explore potential links between COVID-19 and neurodegenerative processes. Molecular modeling predicted a stable RBD-alpha-synuclein complex, confirmed immunochemically. Spectral analysis revealed interaction without secondary structure changes. Importantly, the RBD significantly inhibited alpha-synuclein amyloid transformation, and the resulting fibrils showed reduced cytotoxicity. This suggests that the RBD may not exacerbate, but rather mitigate, alpha-synuclein amyloid aggregation.
Publisher
Biomedicines
Published On
Feb 09, 2023
Authors
Yulia Stroylova, Anastasiia Konstantinova, Victor Stroylov, Ivan Katrukha, Fedor Rozov, Vladimir Muronetz
Tags
SARS-CoV-2
alpha-synuclein
Parkinson's disease
amyloid aggregation
neurodegeneration
molecular modeling
cytotoxicity
Related Publications
Explore these studies to deepen your understanding of the subject.